SHFM3 Activators
SHFM3 activators encompass a diverse array of chemical compounds that indirectly promote the functional activity of SHFM3 through modulation of specific signaling pathways. Forskolin and IBMX exert their effects by increasing intracellular cAMP levels, which subsequently activate PKA and could therefore enhance SHFM3's functional activity by phosphorylating related substrates. Similarly, PMA, as a PKC activator, and Ionomycin, through its ability to elevate intracellular calcium, may activate protein kinases that are capable of enhancing SHFM3 signaling. Epigallocatechin gallate and LY294002 operate by inhibiting kinases and PI3K, respectively, shifting the cellular signaling equilibrium to potentially favor SHFM3-involved pathways. Additionally, Sphingosine-1-phosphate acts through G-protein-coupled receptor-mediated pathways, and Thapsigargin disrupts calcium homeostasis, both of which could amplify signaling cascades that lead to SHFM3 activation.
Staurosporine, although a broad-spectrum kinase inhibitor, might paradoxically enhance SHFM3 activity by inactivating kinases that negatively regulate pathways associated with SHFM3. SB203580 and U0126, which target p38 MAPK and MEK1/2 respectively, could indirectly enhance SHFM3 activity by attenuating competing pathways or by channeling signaling flux towards SHFM3-associated processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin increases intracellular cAMP levels, which can lead to activation of PKA. PKA then can phosphorylate specific substrates that may be part of the SHFM3 signaling pathway, thus enhancing SHFM3's functional activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, leading to elevated cAMP levels in cells. This increase in cAMP may enhance SHFM3 activity by stimulating PKA and other cAMP-responsive pathways indirectly associated with SHFM3 functions. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
Phorbol 12-myristate 13-acetate (PMA) is an activator of Protein Kinase C (PKC), which could enhance signaling pathways that result in the functional activation of SHFM3, particularly if SHFM3 function is modulated by PKC-dependent phosphorylation. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $94.00 $259.00 | 2 | |
Ionomycin is a calcium ionophore which elevates intracellular calcium levels, potentially activating calcium-dependent protein kinases that could enhance SHFM3 activity through downstream signaling. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
This compound is known to inhibit certain types of kinases, and could thereby shift signaling equilibria to favor pathways in which SHFM3 is involved, leading to its enhanced activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that by reducing PI3K activity could shift the balance of intracellular signaling, possibly enhancing pathways in which SHFM3 is involved indirectly. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
This bioactive lipid acts as a signaling molecule and can activate signaling pathways that may enhance SHFM3 activity via its G-protein-coupled receptors. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin inhibits the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), leading to increased cytosolic calcium levels that can activate calcium-dependent pathways potentially enhancing SHFM3 activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Though a broad-spectrum kinase inhibitor, staurosporine may lead to activation of specific pathways associated with SHFM3 by inhibiting kinases that negatively regulate SHFM3 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
This inhibitor targets p38 MAPK and could enhance SHFM3 activity by inhibiting competing signaling pathways or by redirecting signaling towards SHFM3-related pathways. | ||||||